Small Pharma, Big Studies.
Xerimis is uniquely positioned to service the specific needs of small to mid-sized pharmaceutical companies. We know that the task of a modern day clinical packaging organization demands excellence in two key areas: an industry-leading knowledge of the landscape and its complexities along with a tireless dedication to client needs. At Xerimis, we understand the unique demands of your project, and we're here, alongside you, every step of the way.
Agile Ability with Global Reach.
The benefits of an international player with the agility of something much more personal
Insights & News
As the clinical supply industry evolves, so does its vernacular. Small molecules are making way for large ones, resulting in genetic therapies. We no longer work in ambient conditions; today, controlled room temperature best describes the handling process. Even the term sponsor company itself evolved from the fact that companies other than R&D pharmaceuticals are running trials.
These are unprecedented times in our industry. The immediate need for COVID-19 treatment and vaccine has created a clinical trials scenario that would’ve been unthinkable just six months ago. Vaccine development typically takes 10-15 years. Yet reports indicate that it took about eight weeks from first receiving the Coronavirus in labs to the first dosing of a test vaccine. Nearly every pharma company examined their commercial and clinical lines to find treatment potential that could help provide relief for the growing number of COVID patients. Now the world eagerly awaits news for effective treatments and ideally a vaccine.
The role of clinical supply is a very crucial link in the supply chain, yet one that is often glossed over by other groups along that chain. Many decisions are made upstream that have direct impacts on what can be done once a project is handed off to you and your team, without much consideration to the impact it has on the management of trials as it relates to dosing, formulation, delays, vendor selection, and perhaps most critically… milestones.